BBC News
image captionThe New European was launched on a short run in 2016 to fight Brexit
A consortium including Mark Thompson and Lionel Barber has conducted a management buy-out of The New European, the make-shift weekly print title initially launched on a four-week run in 2016 to fight Brexit.
TNE was owned by Archant, the local publishing group based in Norwich.
Its chief content officer, former Daily Mirror executive Matt Kelly, led the fund-raising effort, and as of this morning has left Archant to become CEO and editor-in-chief of The New European.
The executive chairman will be Gavin O Reilly, the Irish businessman who was former CEO of Independent News & Media, and whose father Tony was for many years proprietor of The Independent.
Edwin Madu
Share this article
On the 19th of January, Future Africa, together with LocalGlobe, set out to answer this question with an event titled “A 10-year view of Entrepreneurship in Africa”.
To take a detailed look at the future, the event had panels with founders and investors from all parts of the ecosystem.
After a welcome address by Iyinoluwa Aboyeji, Future Africa Co-founder, Remus Brett of LocalGlobe took the virtual stage to moderate the founders’ panel.
This panel included: Eden Co-Founder/CEO Nadayar Enegesi, Piggyvest Co-Founder/COO Odunayo Eweniyi, Indicina Co-Founder/MD Yvonne Johnson, and Co-Founder & Chair, Andela Advisory Board, Christina Sass.
Share this article
Share this article
LONDON and BUDAPEST, Hungary, Jan. 7, 2021 /PRNewswire/ Turbine, a company simulating cellular decision making to unlock novel oncology therapies, today announces the successful closing of its pre-Series A round by raising EUR 5.7 million (USD 6.85m). The transatlantic round was led by new investor Accel and included XTX Ventures and Boston Millenia Partners who joined the existing syndicate comprising Delin Ventures, Atlantic Labs and o2h Ventures.
Most wet-lab experiments offer limited insight into the complex underlying biology of the disease. As a result, existing preclinical models in oncology often fail to translate into successful drugs in the clinic. To improve these outcomes, Turbine has created the Simulated Cell™ comprising an advanced digital model of human cell behaviour and cloud-based simulated experiments. The Simulated Cell™ can rapidly run unlimited number of experiments in comparison to wet-lab methods.